Completed NA INTERVENTIONAL 2-arm NCT02011022

Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies (HDMTX)

Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Significant Impact Factors and Establishment of a Clinically Relevant Model

Sponsor: The Children's Hospital of Zhejiang University School of Medicine

Conditions Methotrexate Adverse Reaction

Interventions 3g MTX 5g MTX

Updated 5 times since 2017 Last updated: Dec 10, 2013 Started: May 31, 2009 Primary completion: Dec 31, 2009 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02011022, this NA trial focuses on Methotrexate Adverse Reaction and remains completed. Sponsored by The Children's Hospital of Zhejiang University School of Medicine, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Children's Hospital of Zhejiang University School of Medicine

Data source: The Children's Hospital of Zhejiang University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China